10x Genomics, Inc.
TXGNASDAQHealthcare● Active
$29.65
$-1.39(-4.49%)
Market Cap$3.8B
P/E Ratio—
52W High$32.31
52W Low$8.945
10x Genomics, Inc. (TXG) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TXG · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.64B | $0.61B | $0.62B | $0.52B | $0.49B |
| Cost of Revenue | $0.20B | $0.20B | $0.21B | $0.12B | $0.07B |
| Gross Profit | $0.44B | $0.41B | $0.41B | $0.40B | $0.42B |
| Gross Margin %(computed) | 69.05% | 67.86% | 66.15% | 76.69% | 84.89% |
| Operating Expenses | |||||
| R&D Expenses | $0.24B | $0.26B | $0.27B | $0.27B | $0.21B |
| G&A Expenses | $0.00B | $0.34B | $0.00B | $0.29B | $0.25B |
| Total Operating Expenses | $0.55B | $0.61B | $0.67B | $0.56B | $0.47B |
| Operating Income | ($0.11B) | ($0.19B) | ($0.27B) | ($0.17B) | ($0.05B) |
| Operating Margin %(computed) | -17.25% | -31.85% | -42.88% | -32.52% | -10.79% |
| Interest Income | $0.02B | $0.02B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.04B) | ($0.18B) | ($0.25B) | ($0.16B) | ($0.05B) |
| Income Tax Expense | $0.00B | $0.00B | $0.01B | $0.00B | $0.00B |
| Net Income | ($0.04B) | ($0.18B) | ($0.26B) | ($0.17B) | ($0.06B) |
| Net Margin %(computed) | -6.77% | -29.90% | -41.23% | -32.15% | -11.87% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 |
| Wtd Avg Shares | 0.12B | 0.12B | 0.12B | 0.11B | 0.11B |
| EBITDA | ($0.11B) | ($0.13B) | ($0.21B) | ($0.13B) | ($0.02B) |
| EBITDA Margin %(computed) | -17.25% | -21.94% | -33.15% | -24.88% | -5.01% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more 10x Genomics, Inc. data
About 10x Genomics, Inc. (TXG) Income Statement
10x Genomics, Inc. (TXG) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TXG reported revenue of $0.64B, gross profit of $0.44B (gross margin 69.05%), and net income of ($0.04B) — a net profit margin of -6.77%.
Frequently asked questions
TXG · 4 questions10x Genomics, Inc. (TXG) reported revenue of $0.64B for 2025, up 5.2% year-over-year.
TXG revenueTXG salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08